我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1986
已完成
4
50.0%
招募中
暂无批准数据
- Several companies are advancing novel therapies for spinal muscular atrophy (SMA), with over 20 treatments currently in clinical development. - Roche is conducting a Phase IV open-label study to assess the effectiveness and safety of risdiplam in pediatric SMA patients following gene therapy. - Biogen is evaluating higher doses of intrathecally administered nusinersen to improve clinical efficacy in SMA patients. - Novartis is studying the safety and efficacy of intrathecal OAV101 in SMA patients who have discontinued nusinersen or risdiplam treatment.
